Atrium Therapeutics, Inc. Common Stock
RNA
$8.41+1.82%
End of day · as of Oct 10, 2026, 8:01 AM ET
Mkt cap
$217.50M
EV/Sales
-8.80
P/E ratio
N/A
FY2025 Revenue
$18.75M
EPS (H1 2026)
$-2.15
Gross Margin (FY2025)
N/A
Profit Margin (FY2025)
-3650.39%
Beta
N/A
Div yield
N/A
Sector
Healthcare
Atrium Therapeutics, Inc. Common Stock (RNA) is a biotechnology company listed on NASDAQ.
Latest reported RNA revenue for 2025-12-31 was $18.8M. Net income was -$684.6M. Revenue was up 72.1% from 2024-12-31 to 2025-12-31. RNA currently screens at market cap $217.5M.
Use this RNA research hub for sector, financials, and filings — not a live tape.
Latest cached year on this hub. Full RNA income, balance, and cash tables.
Atrium Therapeutics, Inc. Common Stock (RNA) is a biotechnology company in the Healthcare sector.
Latest cached Atrium Therapeutics, Inc. Common Stock (RNA) revenue for Dec 31, 2025 was $18.8M. Net income was -$684.6M. Statements: https://lician.com/financials/rna
Atrium Therapeutics, Inc. Common Stock (RNA) market capitalization is $217.5M on the latest cached snapshot.
Atrium Therapeutics, Inc. Common Stock (RNA) cached previous close $8.26; day range $8.13 – $8.50; volume 185,971. Session quote: https://lician.com/quote/rna
Atrium Therapeutics, Inc. Common Stock (RNA) latest cached earnings event is "RNA earnings" on Aug 13, 2026. Earnings calendar: https://lician.com/earnings
The latest cached RNA filing is 8-K/A · Oct 9, 2026. Filings: https://lician.com/sec/rna